New hope for brain tumor patients: drug shows promise in slowing recurrent meningioma
NCT ID NCT06275919
First seen Apr 09, 2026 · Last updated Jun 09, 2026 · Updated 9 times
Summary
This study tests a drug called regorafenib in 104 people with recurrent meningioma, a type of brain tumor. The drug works by blocking blood vessel growth that feeds the tumor. The goal is to see if it can slow tumor progression and improve survival. Participants must have a confirmed diagnosis and recent tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.O.U. Città della Salute e della Scienza di Torino
RECRUITINGTorino, Italy
Contact Email: •••••@•••••
Contact
-
A.O.U. Policlinico di Bari
RECRUITINGBari, Italy
Contact Email: •••••@•••••
Contact
-
Azienda Ospedaliera Universitaria Gaetano Martino
RECRUITINGMessina, Italia/Messina, 98124, Italy
Contact Email: •••••@•••••
-
Azienda Ospedaliero Universitaria Careggi
RECRUITINGFlorence, Italy
Contact Email: •••••@•••••
Contact
-
Fondazione IRCCS Istituto Neurologico Carlo Besta
RECRUITINGMilan, Italy
Contact Email: •••••@•••••
Contact
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITINGRoma, Italy
Contact Email: •••••@•••••
Contact
-
Humanitas Cancer Center
RECRUITINGRozzano, Milano, Italy
Contact Email: •••••@•••••
Contact
-
IRCCS Istituto Tumori Regina Elena
RECRUITINGRoma, Italy
Contact Email: •••••@•••••
Contact
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, Italy
Contact Email: •••••@•••••
Contact
-
IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
RECRUITINGMeldola, Forlì-Cesena, Italy
Contact Email: •••••@•••••
Contact
-
Istituto Oncologico Veneto
RECRUITINGPadova, 35128, Italy
Contact Email: •••••@•••••
-
Ospedale Bellaria - AUSL Bologna
RECRUITINGBologna, Italy
Contact Email: •••••@•••••
Contact
-
Ospedale San Paolo
COMPLETEDBari, Italy
-
Ospedale del Mare
RECRUITINGNaples, Italy
Contact
Contact Email: •••••@•••••
-
Policlinico San Martino
RECRUITINGGenova, Italy
Contact Email: •••••@•••••
Contact
-
Policlinico Umberto I - Università Sapienza Roma
NOT_YET_RECRUITINGRoma, Italy
Contact Email: •••••@•••••
Contact
-
Spedali Riuniti
RECRUITINGLivorno, Italy
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.